Press Room

News / Dec 05, 2021

Hovione Cork renews its certification of The Business Working Responsibly Mark

A recognition for CSR practices at the site and its positive impact on both the workplace and the wider community

Hovione wins business working responsibility mark

Recently the Hovione Cork site achieved certification of The Business Working Responsibly Mark for the second time, having first achieved the Mark in 2018. The Mark is the leading independently audited standard for Corporate Social Responsibility (CSR) and Sustainability certification in Ireland and is based on ISO26000. The Mark assessment process involved a root to branch review of Hovione's corporate social responsibility and sustainability management systems across five pillars - Governance, Workplace, Marketplace, Environment and Community.

 

“The awarding of the certification for another 3 years is great recognition of the work and dedication that the team in Cork have to continuously improving and developing the CSR standards and practices at the site and its positive impact on both the workplace and the wider community”, said Louise Dennehy.

Business Working Responsibility Mark logo | Hovione

























 

The process for recertification began in April this year lead by Louise Dennehy, HR Business Partner, Marguerite Lynch, HSE Manager - Environment, Bruno Dias, OpEx Specialist and Maureen O'Leary, Procurement Manager with the audit taking place virtually at the end of October. Along with a full process and documentation review, 4 team members were interviewed by the assessor on their knowledge, awareness and understanding of the company’s CSR activities.

 

You might be also interested in:









 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025